Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Philadelphia, Pennsylvania 19102


Purpose:

PRO 140 2102 is a phase 2b, national, multicenter, randomized, double-blind, placebo-controlled study in order to evaluate the safety and efficacy of PRO 140 (anti-CCR5 monoclonal antibody) administered subcutaneously as an adjunct to a new, optimized, oral antiretroviral regimen in HIV-infected injection drug users with viral rebound and documented poor adherence to the previous antiretroviral regimen.


Criteria:

Key Inclusion Criteria: 1. Only R5 virus 2. HIV-1 RNA > 1,000 copies/mL but < 100,000 copies/mL 3. CD4+ lymphocyte counts > 100 cells/μL 4. Non-prescription recreational drug use within the previous 6 months Key Exclusion Criteria: 1. Females who are pregnant (positive blood test), lactating, or breastfeeding, or who plan to become pregnant during the study 2. Prior use of any CCR5 entry inhibitors 3. History of any acquired immune deficiency syndrome (AIDS)-defining illness


NCT ID:

NCT01272258


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

Philadelphia, Pennsylvania 19102
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.